|
Oct 4
|
Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
|
|
Oct 3
|
First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
|
|
Jul 29
|
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
|
|
Jul 24
|
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
|
|
Jul 23
|
Telix Successfully Prices A$650 Million Convertible Bonds
|
|
Jul 23
|
Telix Announces A$600 Million Convertible Bonds Offering
|
|
Feb 7
|
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
|
|
Feb 7
|
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
|
|
Jan 4
|
Australia's Telix Pharmaceuticals jumps on potential US listing
|
|
Jan 4
|
UPDATE 2-Australia's Telix Pharmaceuticals jumps on potential US listing
|
|
Jan 4
|
Telix Announces Planned Registered Public Offering and Listing in the United States
|
|
Jan 3
|
Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 18
|
Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
|
|
Dec 6
|
Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS
|
|
Dec 4
|
First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent
|
|
Nov 29
|
Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS
|
|
Nov 8
|
Telix to Present at Jefferies London Healthcare Conference 2023
|
|
Nov 8
|
Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region
|
|
Sep 27
|
HRH Princess Astrid of Belgium visits Telix's New European Manufacturing Facility in Brussels South
|
|
Jul 19
|
Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow
|